Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEA117106: Mepolizumab vs placebo as add‑on therapy in frequently exacerbating COPD
2013-004298-28Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Mepolizumab 100 mg SC + standard of care with Placebo SC + standard of care (2 arms). Primary endpoint: Frequency of moderate and severe exacerbations. Started Apr 2014; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2013-004298-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004298-28.